We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation.
- Authors
Masago, Katsuhiro; Togashi, Yosuke; Fukudo, Masahide; Terada, Tomohiro; Irisa, Kaoru; Sakamori, Yuichi; Fujita, Shiro; Kim, Young Hak; Mio, Tadashi; Inui, Ken-ichi; Mishima, Michiaki
- Abstract
Recently, 2 small molecule kinase inhibitors (TKIs), targeting epidermal growth factor receptor (EGFR), have proven effective in the treatment of non-small cell lung cancer. However, it is unknown whether the EGFR double activating mutation of L858R in exon 21 and the in-frame deletion in exon 19 is a predictor of the effectiveness of EGFR-TKIs. We report for the first time a case of non-small cell lung cancer with central nervous system metastases harboring a rare EGFR double activating mutation who showed a good clinical response to erlotinib, regardless of his poor performance status, as swallowing is not possible. Therefore, we suggest that erlotinib may become a therapeutic choice in cases of central nervous system metastases even with poor performance status. Copyright © 2010 S. Karger AG, Basel
- Publication
Case Reports in Oncology, 2010, Vol 3, Issue 2, p98
- ISSN
1662-6575
- Publication type
Article
- DOI
10.1159/000310830